Medication info

Linadia Duo Tablets 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Bright yellow, oval, biconvex film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201903127 · Approved 2019.05.15

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be gradual. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3, Precautions for administration to the following patients, in Precautions for use). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control, so caution and appropriate monitoring are necessary. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications).

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to help patients with type 2 diabetes control their blood sugar levels by using Linagliptin and Metformin together. It is mainly used in conjunction with dietary control and exercise therapy to effectively manage blood sugar. This helps maintain blood sugar levels more stably and contributes to the prevention of complications arising from diabetes. Better treatment outcomes can be expected when it is used alongside improvements in patient lifestyle habits. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be gradual. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment experience whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3, Precautions for administration to the following patients, in Precautions for use). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control, so caution and appropriate monitoring are necessary. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications).

Precautions

This medication may cause serious side effects such as lactic acidosis, so caution is needed. Lactic acidosis is a dangerous condition that occurs when lactic acid builds up excessively in the body, which can be life-threatening without immediate treatment. This medication should not be administered to patients with severely impaired kidney function, poor liver function, weakened heart or lung function, or those with acute infections or dehydration. Additionally, women who are pregnant or breastfeeding should not take this medication. The risk of hypoglycemia exists; therefore, when used with insulin or sulfonylurea class medications, careful monitoring of blood sugar changes is essential. Elderly patients with diminished kidney function should have their kidney function checked regularly and adjust the dosage if necessary. Acute pancreatitis or skin blistering conditions may occur during medication; thus, if severe abdominal pain or skin abnormalities arise, consult a doctor immediately. Gastrointestinal discomfort symptoms (abdominal pain, diarrhea, vomiting, etc.) can occur frequently, so it is recommended to take the medication with meals or after meals. Be cautious of drug interactions, especially when taking other medications that could affect kidney function; close monitoring of kidney function is required. If receiving iodine contrast agents for radiological exams, this medication should be discontinued before and after the examination until kidney function stabilizes. For surgical procedures, this medication should be stopped 48 hours before surgery and can be resumed once kidney function has recovered post-surgery. If planning to become pregnant or if already pregnant, it is recommended to manage blood sugar with insulin therapy instead of this medication. The safety of this medication in children and adolescents has not been established, so it is not recommended for patients in this age group. This medication should be stored out of reach of children in a cool, dry place.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, reduced and deficient vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, blistering pemphigoid, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, viral upper respiratory infection, periodontitis, influenza, mediastinitis, pharyngitis, rhinitis, upper respiratory infection, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, dizziness, drowsiness, chest discomfort, weakness, nosebleed, oropharyngeal pain, voice disorder, epistaxis, hearing loss, erectile dysfunction, goiter, anemia, anxiety, mood disorder, insomnia, depression, hypertension, benign prostatic hyperplasia, disorientation, nocturia, dermatitis, osteoarthritis, limb pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, rotator cuff syndrome, male pattern baldness, hyperhidrosis, hair loss, anxiety, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, laceration, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, thyroid nodule, vitreous hemorrhage, fever, ligament strain, flank pain, myelodysplastic syndrome, vocal fold polyp

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, to maintain drug efficacy, it is important to store it at a cool room temperature, specifically between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright yellow, oval, biconvex film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.